Annexon Biosciences, Inc. (ANNX)
| Market Cap | 840.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.34M |
| Shares Out | 38.16M |
| EPS (ttm) | -4.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $21.78 |
| Previous Close | $21.52 |
| Change ($) | 0.26 |
| Change (%) | 1.21% |
| Day's Open | 21.36 |
| Day's Range | 21.36 - 22.34 |
| Day's Volume | 68,440 |
| 52-Week Range | 15.33 - 38.01 |
SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for pa...
Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) ...
SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with c...
Thomas G. Wiggans appointed Chairman Thomas G. Wiggans appointed Chairman
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, engages in developing therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its products in pipelines are focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. Its products include ANX005 (IV), which is in Phase III stage with guillain-barré syndrome indication, as well as in Phase II stage with warm autoimmune hemolytic anemia, huntington's disease, and amyotrophic lateral sclerosis indications; ANX007 (... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol ANNX |
Analyst Forecasts
According to 3 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price forecast is 37.00, which is an increase of 69.88% from the latest price.